Adma Biologics Inc. (ADMA)
NASDAQ (NMS) NASDAQ (NMS) Primary 
ADMA Biologics: Business Update And My Price Target
ADMA Biologics was trading poorly in early 2021, near $2 per share. My thesis centered on ADMA's asset value, including plasma centers, matching its enterprise value. Strong revenue growth, insider buying, and a poison pill signaled management's confidence in profitability.
Adma Biologics (ADMA) Sees a More Significant Dip Than Broader Market: Some Facts to Know
In the latest trading session, Adma Biologics (ADMA) closed at $17.7, marking a -1.28% move from the previous day.
ADMA Biologics Reports Preliminary 2025 Results, Ups 2026 Outlook
ADMA expects 2025 revenues of approximately $510-$511 million, raising 2026 guidance on strong Asceniv demand and margin expansion.
Is Adma Biologics (ADMA) a Buy as Wall Street Analysts Look Optimistic?
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?
ADMA Biologics, Inc. (ADMA) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
ADMA Biologics, Inc. (ADMA) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Why Adma Biologics (ADMA) Outpaced the Stock Market Today
In the most recent trading session, Adma Biologics (ADMA) closed at $18.34, indicating a +1.72% shift from the previous trading day.
Is ADMA Biologics (ADMA) Stock Outpacing Its Medical Peers This Year?
Here is how Adma Biologics (ADMA) and Artivion (AORT) have performed compared to their sector so far this year.
Adma Biologics (ADMA) Up 43.3% Since Last Earnings Report: Can It Continue?
Adma Biologics (ADMA) reported earnings 30 days ago. What's next for the stock?
Brokers Suggest Investing in Adma Biologics (ADMA): Read This Before Placing a Bet
The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.
Adma Biologics (ADMA) Upgraded to Buy: Here's What You Should Know
Adma Biologics (ADMA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Is ADMA Biologics (ADMA) Outperforming Other Medical Stocks This Year?
Here is how Adma Biologics (ADMA) and Cronos Group (CRON) have performed compared to their sector so far this year.
Adma Biologics (ADMA) Recently Broke Out Above the 200-Day Moving Average
After reaching an important support level, Adma Biologics (ADMA) could be a good stock pick from a technical perspective. ADMA surpassed resistance at the 200-day moving average, suggesting a long-term bullish trend.
